Navigation Links
Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
Date:10/30/2008

RICHMOND, Va., Oct. 30 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today reported results for the third quarter and nine-months ended September 30, 2008.

Recent Company Highlights

-- Follow-on Biologics Program

-- Received approval from the United Kingdom's Medicines and

Healthcare products Regulatory Agency to initiate a Phase I clinical

study for the Company's second follow-on biologic

("FOB") product candidate, INS-20. Insmed's INS-20

is a pegylated recombinant form of human G-CSF, and an FOB of the

FDA-approved product Neulasta(R), which had U.S. sales of

approximately $2.4 billion in 2007.

-- IPLEX(TM)

-- Received $3.0 million in cost recovery revenue in the third quarter

related to the expanded access program ("EAP") for

IPLEX(TM). The EAP in Italy to treat patients with Amyotrophic

Lateral Sclerosis ("ALS"), also known as Lou Gehrig's

Disease, currently includes 23 physicians and over 100 subjects have

enrolled;

-- Announced the presentation of clinical study results with Premacure

demonstrating IPLEX(TM) increased serum IGF-I levels into the normal

range in significantly premature infants. Premacure is developing

IPLEX(TM) as a potential treatment for Retinopathy of Prematurity

("ROP") via a Material Transfer Agreement with Insmed.

Based in part on the results of this study, Premacure intends to

initiate a phase II multicenter trial in the ROP indication during

the fourth quarter.

"We continue to execute on our business plan and efficiently advance each of our key clinical programs," said Dr. Geoffrey Allan, President and CEO of Insmed. "Our second FOB ca
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
2. Insmed Announces That NASDAQ Temporarily Suspends Minimum Bid Closing Price Rule
3. Insmed to Seek Shareholder Approval for Reverse Split
4. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
5. Insmed to Present at Biosimilars 2008 Conference
6. Insmed to Present at BioPharm Asia 2008 Conference
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. Insmed CEO to Present at Drug Discovery & Development Conference
9. Insmed to Host Second Quarter 2008 Conference Call
10. Insmed Partners With Bill Thomas, Former House Ways and Means Chairman, as Strategic Advisor
11. Insmed Retains RBC Capital Markets as Strategic Financial Advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... ... August 26, 2015 , ... ... investment in the development and manufacture of highly valued cardiac markers used in ... team's extensive expertise with protein chemistry has led to the development and commercialization ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
(Date:8/26/2015)... BEIJING , August 26, 2015 Israel ... DiaCardio wins 1 st place  Wayerz comes ... in Israel by venture capital fund JVP, ... including the US, China , Israel ... America .  Impressive achievement for the Israeli representatives ...
(Date:8/26/2015)... August 26, 2015 After litigating and ... NV relating to P2i United States ... dispute in the United States without ... part of either party. As a result of the parties, ... California dismissed the case without prejudice. ...
Breaking Biology Technology:Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6P2i Settles United States Litigation 2
... critical care clinicians, ... DURHAM, N.C., July 24 bioMerieux recently ... Thoracic Society and,Society of Hospital Medicine, that show ... are unanimous in their view that,new methods and ...
... Instrumentation Laboratory,(IL) today announced that Broadlane, Inc., ... Company with a five-year contract covering its,critical care ... counts,among its clients more than 915 acute care ... than 18,000 physician practices., The contract covers ...
... The Global Probiotics Council,(GPC), a committee established ... Ltd., announced the two awardees who will receive ... today. The program was,created to identify young rising ... of probiotics and gut microbiota research in the ...
Cached Biology Technology:U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 2U.S. Clinicians Indicate a Strong Need for New Tools to Combat Sepsis 3Instrumentation Laboratory Announces Contract for Multi-Parameter Testing Products with Broadlane 2Global Probiotics Council Announces First Awardees for New Young Investigator Grant for Probiotics Research 2Global Probiotics Council Announces First Awardees for New Young Investigator Grant for Probiotics Research 3Global Probiotics Council Announces First Awardees for New Young Investigator Grant for Probiotics Research 4
(Date:8/3/2015)... JOSE, Calif. , Aug. 3, 2015 ... of human interface solutions, today announced that members of ... community at the Pacific Crest Global Technology Leadership Forum ... Time. The conference will be held at the Sonnenalp ... The presentation may include forward-looking information. An ...
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... have worked to solve the mystery of why adult coho ... from the ocean to mate and spawn. In a study ... team use models to estimate the potential impact of urban ... Stricken coho salmon ( Oncorhynchus kisutch ) show a ...
... astounding evolutionary event occurred: certain bacteria became obliged to ... events that resulted in what is now the mitochondria, ... recent study by researchers at the University of Hawaii ... provides strong evidence that mitochondria share a common evolutionary ...
... Jacinta Conrad, an assistant professor of chemical and ... research into how bacteria move to "tracking bright spots ... to a microscope, Conrad and her collaborators videotape hours ... thousands of images to determine exactly how they cross ...
Cached Biology News:Models show Coho salmon at risk in US urbanizing watersheds 2Mitochondria share an ancestor with SAR11, a globally significant marine microbe 2University of Houston professor co-authors PNAS paper on how bacteria move 2
Limit of detection: <5 pg/ml...
... custom siRNA service provides the premium quality ... research. Custom siRNAs can be readily ordered ... target sequence, or by providing the sense ... Ambion's Silencer Validated and Silencer Pre-designed siRNAs, ...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
, Premium quality synthesis and purification , You provide the sequence, we'll do the rest , Rigorous quality control , Your choice of purification method, amount and format , Available annealed...
Biology Products: